Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

University of Florida, Gainesville, and a lead investigator in this Phase IIb study.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and a leading cause of cirrhosis, liver cancer and the need for liver transplants. According to the Centers for Disease Control and Prevention (CDC), an estimated 4.1 million Americans (1.6 percent) have been infected with hepatitis C; 3.2 million are chronically infected. The number of new infections per year has declined from an average of 240,000 in the 1980s to about 26,000 in 2004. CDC estimates the number of hepatitis C-related deaths could increase to 38,000 annually by the year 2010, surpassing annual HIV/AIDS deaths.

About PEGASYS

PEGASYS, in combination with COPEGUS (ribavirin), are indicated for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). In addition, PEGASYS in combination with COPEGUS is the first and only FDA-approved regimen for the treatment of chronic hepatitis C in patients coinfected with hepatitis C and HIV. PEGASYS is the only pegylated interferon indicated for the treatment of adult patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation).

PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is administered orally two times a day as a split dose. Roche has backed PEGASYS with the most extensive clinical research program ever undertaken in hepatitis C, with major studies initiated to advance treat
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 For its innovative modular ... , Art,s-Way Scientific has earned a Modular Building ... competition in over 30 categories, MBI,s contest is the ... which include building manufacturers, dealers, and product and service ... example the capability of our team," said Dan ...
(Date:7/31/2014)... , July 31, 2014 genae, a global ... announced today the incorporation of genae UK in London ... has one of the largest medical device markets in the world. ... is projected to increase by a CAGR of 6.0% until 2017. ... to 9.5% of GDP. Despite recessionary pressures, market growth rates over ...
(Date:7/31/2014)... , July 31, 2014 TB Alliance, ... developing better, faster and affordable treatments, announced the ... Vice President, External Affairs. Mr. Brock comes to ... of Major Donor Relations for WWF International (formerly ... role, Mr. Brock will guide the TB Alliance,s ...
Breaking Medicine Technology:Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4genae Opens Offices in London 2TB Alliance Appoints Willo Brock Senior Vice President, External Affairs 2
... BRAUNFELS, Texas , May 21 The SCOOTER Store is ... Science Center San Antonio, believing that teaching ethics and humanitarian values to ... elderly. , , , ... of The SCOOTER Store is to create an opportunity for every American ...
... BOSTON , May 21  Solos Endoscopy, Inc. (Pink ... to its board of directors as Chief Financial Officer. Mr. Schiemann ... as expertise in taxation, auditing and public securities work. , ... Mr. Schiemann previously served as the Chief ...
Cached Medicine Technology:The SCOOTER Store Invests in Ethics Training for Future Doctors 2The SCOOTER Store Invests in Ethics Training for Future Doctors 3Solos Endoscopy, Inc. Appoints Experienced CFO To Financial Leadership Amidst Growth 2
(Date:7/31/2014)... Setting goals for a fitness program is very ... to weight loss. Fitness on the Go has been helping ... has worked with 6000 customers on an individual basis throughout ... to monitor why customers start exercising with a personal ... to their program, whether or not they have a goal ...
(Date:7/31/2014)... The VitalSleep anti snoring device is a mandibular advancement splint ... snorers airway to quiet snoring. , Dawn M. of Utah ... her husband by allowing them to share the same bedroom again. ... about 15 years ago and I remember nights when it was ... had to head downstairs for any relief. As the years have ...
(Date:7/31/2014)... York (PRWEB) July 31, 2014 ... as Bernstein Liebhard LLP notes that Johnson & ... plans to voluntarily remove its power morcellators ( ... report from Bloomberg.com, the company said it decided ... associated with the devices remain uncertain.* , “In ...
(Date:7/31/2014)... London, UK (PRWEB) July 31, 2014 ... in the development and maintenance of products in the ... can be performed by using various products and equipment ... and spoilage of various materials and products. , ... and services is forecast to post a CAGR of ...
(Date:7/31/2014)... HealthDay Reporter THURSDAY, July 31, 2014 (HealthDay ... has shown an increased risk of spreading undetected cancers in ... market. In a letter that was to be sent ... that its laparoscopic power morcellators be returned to the company, ... of new morcellators had been suspended in April after the ...
Breaking Medicine News(10 mins):Health News:Fitness on the Go's Rewards Program Helps Clients Reach Their Goals 2Health News:New Snoring Mouthpiece Reviews from VitalSleep 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 3Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 2Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 3Health News:J&J Pulls Hysterectomy Tool Tied to Cancer Risk From Market 2Health News:J&J Pulls Hysterectomy Tool Tied to Cancer Risk From Market 3
... Designs Founder,Cynthia Shapiro Reveals the Importance in Protecting Your Eyes ... In Style ... ... 3 Cinzia Designs announces the,Top 5 Tips for protecting your eyes in ... sun safety awareness. This,year Sun Safety Week is June 1st through June 7th. ...
... facility, first in the Northwest, is ,unlike a,traditional ... will admit its first,patients on Monday, June 23 ... Broadway on Seattle,s First Hill. Five years in ... innovative facility is the,first of its kind in ...
... Quarterly Reports Utilize Strategic Intelligence and Competitive Analysis, from Thomson ... of Information on Medical Research and the U.S. Generics ... ... and PHILADELPHIA, June 4 Thomson Reuters, the,world,s leading source of ...
... chief,science officer for the Grocery Manufacturers Association (GMA), today,released ... Science in,the Public Interest,s petition to the US Food ... require food label warning statements,and to revise FDA public ... affirmed through extensive review by,the US Food & Drug ...
... and the Pennsylvania,Association of Community Bankers team up for ... Batter Up! It,s time to,break out your cleats ... Breast Cancer Coalition (PBCC) and the Pennsylvania,Association of Community ... to each of the 11 Minor League Baseball Stadiums ...
... Stop Strokes, WASHINGTON, June 3 In ... saving brain tissue and preventing disability or even,death. ... and,remove blood clots in the brain through catheter-based ... a heart attack. To train,interventional cardiologists and vascular ...
Cached Medicine News:Health News:Protect Your Eyes in Style: Cinzia Designs Offers Top Tips for Protecting Your Eyes This Summer 2Health News:Protect Your Eyes in Style: Cinzia Designs Offers Top Tips for Protecting Your Eyes This Summer 3Health News:Swedish Orthopedic Institute Opens in Seattle 2Health News:Swedish Orthopedic Institute Opens in Seattle 3Health News:Swedish Orthopedic Institute Opens in Seattle 4Health News:Swedish Orthopedic Institute Opens in Seattle 5Health News:Swedish Orthopedic Institute Opens in Seattle 6Health News:The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline 2Health News:The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline 3Health News:Grocery Manufacturers Association: US Food & Drug Administration and European Food Safety Authority Affirm Safety of Certified Food Dyes 2Health News:Take a Swing Against Breast Cancer! 2Health News:Unique Simulation Training Course Ushers in New Era of Stroke Intervention 2Health News:Unique Simulation Training Course Ushers in New Era of Stroke Intervention 3Health News:Unique Simulation Training Course Ushers in New Era of Stroke Intervention 4
... A disposable lever action ... angled head that is designed ... of your work from your ... Staplers are available in four ...
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
100L...
Medicine Products: